To the latest research, no direct causal relationship between the use of TNF-alpha or other biological agents (e.g., anti-IL 12/23, anti IL-17, and anti IL-23, also anecdotically used in HS patients) and tumours development were reported. This evidence concerns the gene IL17A and histiocytic sarcoma.